Rectal Carcinoma Clinical Trial
Official title:
Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma
Total mesorectal excision (TME) is a precise dissection of the rectum and all para-rectal
lymph nodes within the mesorectal envelope. It is becoming universally recognized and
accepted as the standard technique for surgical excision of rectum carcinomas. TME results
in lowest rates of local recurrence, especially when combined with pre-operative
chemo-radiotherapy.
Especially after pre-operative chemo-radiotherapy, the post-operative drainage may be
important. The quick decrease of this drainage will enable the early mobilisation of the
patient and may shorten the time of hospitalization. If this decrease in fluid production
can be achieved, it will have a positive effect on the Quality of Life of the patient and
will ensure health economic savings by reduction of hospitalization time and resources.
Somatostatin analogues have shown to be able to decrease the secretion of numerous types of
bodily fluids.
The aim of this study is to investigate if lanreotide Autogel 120mg is capable to reduce the
fluid discharge in patients that underwent a TME for rectumcarcinoma.
Lanreotide Autogel 120mg compared to placebo, administered post-surgery on the fluid
discharge in the drain of the patient that underwent a total mesorectum excision (TME) for
rectal carcinoma. Patient planned to have a TME will be asked to participate in the study.
When they have provided written informed consent, they will be randomized 1:1 to receive
either placebo or lanreotide autogel 120mg. Drain fluid will be checked for hematocrit daily
post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication or
placebo will be administered. After administration the volume of the drain fluid will be
measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected
every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and
chloride analysis afterwards. If the patient has a hematocrit >10% in his drain fluid for a
period of 5 days, this patient can not be randomized.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01227239 -
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting
|
Phase 1/Phase 2 | |
Recruiting |
NCT01459328 -
Resource-Sparing Curative Treatment for Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT04078828 -
PR in Endoscopic LAR for Rectal Cancer
|
N/A | |
Not yet recruiting |
NCT06424522 -
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
|
Early Phase 1 | |
Terminated |
NCT02797405 -
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
|
N/A | |
Completed |
NCT01751516 -
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
|
||
Terminated |
NCT01111292 -
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
|
Phase 1/Phase 2 | |
Completed |
NCT00682786 -
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
|
Phase 2 | |
Completed |
NCT02000050 -
Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)
|
Phase 2 | |
Recruiting |
NCT04749108 -
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01696981 -
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
Active, not recruiting |
NCT01899547 -
Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum
|
N/A | |
Completed |
NCT01333709 -
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT04848311 -
Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253
|
N/A | |
Not yet recruiting |
NCT02770911 -
Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02817126 -
Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer
|
N/A | |
Completed |
NCT02551237 -
Neoadjuvant Treatment for Advanced Rectal Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT04713618 -
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
|